[¹¹C]Methionine PET, Histopathology, and Survival in Primary Brain Tumors and Recurrence

References

1. ↵
   DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114–23

   CrossRefPubMedWeb of Science
2. Berg G, Blomquist E, Cavallin-Stahl E. A systematic overview of radiation therapy effects in brain tumours. Acta Oncol 2003;42:582–88

   CrossRefPubMedWeb of Science
3. Barker FG, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998;42:709–20

   PubMedWeb of Science
4. ↵
   Kondziolka D, Flickinger JC, Bissonette DJ, et al. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 1997;41:776–83

   CrossRefPubMed
5. ↵
   Mirzaei S, Knoll P, Kohn H. Diagnosis of recurrent astrocytoma with fludeoxyglucose F18 PET scanning. N Engl J Med 2001;344:2030–31

   CrossRefPubMed
6. ↵
   Goldman S, Levivier M, Pirotte B, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098–106

   CrossRefPubMedWeb of Science
7. ↵
   Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and ¹¹C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004;45:1293–98

   Abstract/FREE Full Text
8. ↵
   Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861–67

   Abstract/FREE Full Text
9. Barker FG, Chang SM, Valk PE, et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115–26

   CrossRefPubMedWeb of Science
10. Chao ST, Suh JH, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001;96:191–97

    CrossRefPubMedWeb of Science
11. ↵
    Di CG, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988;150:189–97

    CrossRefPubMedWeb of Science
12. ↵
    Ribom D, Eriksson A, Hartman M, et al. Positron emission tomography ¹¹C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541–49

    CrossRefPubMedWeb of Science
13. ↵
    Brock CS, Young H, O’Reilly SM, et al. Early evaluation of tumour metabolic response using [¹⁸F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608–15

    CrossRefPubMedWeb of Science
14. ↵
    Ishiwata K, Kubota K, Murakami M, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993;34:1936–43

    Abstract/FREE Full Text
15. ↵
    Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45

    Abstract/FREE Full Text
16. ↵
    Ribom D, Engler H, Blomquist E, et al. Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med Mol Imaging 2002;29:632–40

    CrossRefPubMed
17. ↵
    Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000;48:43–52

    CrossRefPubMedWeb of Science
18. ↵
    Sonoda Y, Kumabe T, Takahashi T, et al. Clinical usefulness of ¹¹C-MET PET and ²⁰¹T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 1998;38:342–47

    CrossRefPubMed
19. ↵
    Ogawa T, Kanno I, Shishido F, et al. Clinical value of PET with 18F-fluorodeoxyglucose and l-methyl-¹¹C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991;32:197–202

    PubMedWeb of Science
20. ↵
    Pirotte B, Goldman S, Salzberg S, et al. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg 2003;38:146–55

    CrossRefPubMedWeb of Science
21. ↵
    Pirotte B, Goldman S, Van BP, et al. Integration of [¹¹C]methionine-positron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. Neurosurgery 2005;57:128–39

    CrossRefPubMedWeb of Science
22. ↵
    Levivier M, Wikler D, Jr., Massager N, et al. The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 2002;97:542–50

    PubMedWeb of Science
23. ↵
    Meyer PT, Schreckenberger M, Spetzger U, et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med 2001;28:165–74

    CrossRefPubMed
24. ↵
    Dropcho EJ, Soong SJ. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology 1996;47:684–90

    Abstract/FREE Full Text
25. ↵
    Kracht LW, Friese M, Herholz K, et al. Methyl-[¹¹C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868–73

    CrossRefPubMed
26. ↵
    Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85

    Abstract/FREE Full Text
27. ↵
    Derlon JM, Bourdet C, Bustany P, et al. [¹¹C]l-methionine uptake in gliomas. Neurosurgery 1989;25:720–28

    CrossRefPubMedWeb of Science
28. ↵
    Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45–53

    PubMedWeb of Science
29. ↵
    Utriainen M, Metsahonkala L, Salmi TT, et al. Metabolic characterization of childhood brain tumors: comparison of ¹⁸F-fluorodeoxyglucose and ¹¹C-methionine positron emission tomography. Cancer 2002;95:1376–86

    CrossRefPubMedWeb of Science
30. ↵
    Souba WW, Pacitti AJ. How amino acids get into cells: mechanisms, models, menus, and mediators. JPEN J Parenter Enteral Nutr 1992;16:569–78

    Abstract/FREE Full Text
31. ↵
    Bading JR, Kan-Mitchell J, Conti PS. System A amino acid transport in cultured human tumor cells: implications for tumor imaging with PET. Nucl Med Biol 1996;23:779–86

    CrossRefPubMed
32. ↵
    Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459–62

    Abstract/FREE Full Text
33. ↵
    Kiessling F, Krix M, Heilmann M, et al. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography. Invest Radiol 2003;38:516–24

    CrossRefPubMedWeb of Science
34. ↵
    Bogin L, Margalit R, Mispelter J, et al. Parametric imaging of tumor perfusion using flow- and permeability-limited tracers. J Magn Reson Imaging 2002;16:289–99

    CrossRefPubMed
35. ↵
    Sasajima T, Miyagawa T, Oku T, et al. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging 2004;31:1244–56

    PubMedWeb of Science
36. ↵
    Jacobs A. Amino acid uptake in ischemically compromised brain tissue. Stroke 1995;26:1859–66

    Abstract/FREE Full Text
37. ↵
    Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 2003;13:269–71

    CrossRefPubMed
38. ↵
    Herholz K, Holzer T, Bauer B, et al. ¹¹C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316–22

    Abstract/FREE Full Text
39. ↵
    De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–50

    CrossRefPubMedWeb of Science
40. ↵
    Weckesser M, Matheja P, Schwarzrock A, et al. Prognostic significance of amino acid transport imaging in patients with brain tumors. Neurosurgery 2002;50:958–64

    CrossRefPubMed
41. ↵
    Schmidt D, Gottwald U, Langen KJ, et al. 3-[¹²³I]Iodo-alpha-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. Eur J Nucl Med 2001;28:855–61

    CrossRefPubMed
42. ↵
    Van LK, Ceyssens S, Van CF, et al. Direct comparison of ¹⁸F-FDG and ¹¹C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39–51

    CrossRefPubMedWeb of Science
43. ↵
    Kim S, Chung JK, Im SH, et al. ¹¹C-methionine PET as a prognostic marker in patients with glioma: comparison with ¹⁸F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:52–59

    CrossRefPubMed
44. ↵
    Giammarile F, Cinotti LE, Jouvet A, et al. High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol 2004;68:263–74

    CrossRefPubMed
45. ↵
    Chung JK, Kim YK, Kim SK, et al. Usefulness of ¹¹C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on ¹⁸F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:176–82

    CrossRefPubMed
46. ↵
    Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[¹⁸F]Fluorethyl)-l-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422–29

    CrossRefPubMedWeb of Science
47. ↵
    Choi SJ, Kim JS, Kim JH, et al. [¹⁸F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005
48. ↵
    Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with ¹⁸F-FLT PET: comparison with ¹⁸F-FDG. J Nucl Med 2005;46:945–52

    Abstract/FREE Full Text